The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer

Abstract

Purpose MicroRNAs (miRNAs) have potential prognostic value for colorectal cancers (CRCs); however, their value based on patient race/ethnicity and pathologic stage has not been determined. The goal was to ascertain the prognostic value of 5 miRNAs with increased expression in CRCs of African American (Black) and non-Hispanic Caucasian (White) patients. Experimental Design TaqMan® qRT-PCR was used to quantify expression of miR-20a, miR-21, miR-106a, miR-181b, and miR-203 in paired normal and tumor CRC archival tissues collected from 106 Black and 239 White patients. The results were correlated with overall survival based on patient race/ethnicity and pathologic stage. Since decisions regarding adjuvant therapy are important for Stage III CRCs, and since miR-181b appeared to have prognostic value only for Stage III Black patients, we assessed its prognostic value in a separate cohort of Stage III CRCs of Blacks. Results All 5 miRNAs had higher expression in CRCs (>1.0-fold) than in corresponding normal tissues. High expression of miR-203 was associated with poor survival of Whites with Stage IV CRCs (HR=3.00, 95% CI=1.29–7.53), but in Blacks it was an indicator of poor survival of patients with Stage I and II CRCs (HR=5.63, 95% CI=1.03–30.64). Increased miR-21 expression correlated with poor prognosis for White Stage IV patients (HR=2.50, 95% CI=1.07–5.83). In both test and validation cohorts, high miR-181b expression correlated with poor survival of only Black patients with Stage III CRCs (HR=1.94, 95% CI=1.03–3.67). Conclusion These preliminary findings suggest that the prognostic value of miRNAs in CRCs varies with patient race/ethnicity and stage of disease.

MicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapy

“…miR-143 was then found to be down-regulated in colon but not in rectum related cancer DOI:http://dx.doi.org/10.7314/APJCP.2014.15.17.6989 MicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapies (Akao et al, 2006a, Xi et al, 2007, Vogelstein et al, 1988 NF2, CCND, miR-1 Down MET (Reid et al, 2012) miR-7 Down, up XRCC2, YY1,PAX6, (Motoyama et al, 2009, Xu et al, 2014, Zhang et al, 2013c, Li et al, 2014b) miR-9 Down α-Catenin (Cekaite et al, 2012, Zhu et al, 2012) miR-10b Down (Nishida et al, 2012, Burk et al, 2008, Zhu et al, 2012) miR-16 Down Cdx2 (Ma et al, 2013, Volinia et al, 2006, Tagawa et al, 2012 Up THBS1, MYC, CDKN1A,TMBIM1, E2F1 (Lanza et al, 2007, Arndt et al, 2009, Volinia et al, 2006, Motoyama et al, 2009, Diosdado et al, 2009, Cummins et al, 2006 Up ATM (Cummins et al, 2006, Sarver et al, 2009, Arndt et al, 2009, Wang et al, 2010, Wu et al, 2013a Up TF (Diosdado et al, 2009, Yu et al, 2013a, Bandres et al, 2006, Cummins et al, 2006 Up SFPQ and MYBL2 (Cummins et al, 2006, Arndt et al, 2009, Kurokawa et al, 2012 Up PTEN, TMP1 (Tan et al, 2013, Bovell et al, 2013, Earle et al, 2010, Yantiss et al, 2009…”

Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets

“…Therefore, miR-203 is involved in tumor cell differentiation, proliferation and metastasis, and is thought to be a tumor suppressor. However, upregulation of miR-203 has been found in multiple tumor types including colorectal cancer [26, 32, 36], pancreatic cancer [34, 35, 37], renal cell carcinoma [28], breast cancer [25, 33] and ovarian cancer [31], indicating that miR-203 may also exhibit oncogenic potential, likely due to its ability to induce MET and promote metastatic colonization at distant sites [26]. Thus, it is controversial that whether miR-203 expression can be used as a prognostic biomarker in cancer.…”

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer

“…An miRNA signature associated with complete response to neoadjuvant chemotherapy in rectal cancers has also been reported [62]. Recent findings by Bovell et al [63] suggest that the prognostic value of miR-21 and other miRNA biomarkers may be dependent on race/ethnicity in advanced cancers. Regardless, whereas such assays may prove useful for predicting chemotherapeutic response in patients with stage II miRNA profiles have also been evaluated for their ability to predict response to anti-EGFR therapy.…”